ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Coya Therapeutics (COYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $14.00 price target on the stock.